The Fred Hutchinson/University of Washington Cancer Consortium is a new entity formed from the Fred Hutchinson Cancer Research Center, a comprehensive cancer center and 30-year CCSG recipient, and its strong collaborators, the University of Washington and Children's Hospital. The consortium brings roger nearly 300 faculty with research interes_ in _, clinicaq-and public health sciences related to cancer, with a total NCI funding of $112 million. The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. New opportunities to reduce the suffering and mortality from cancer are to be found in the interdisciplinary collaboration of scientists in basic, clinical and public health sciences exploiting new information and technology. The Consortium faculty are organized into 16 productive research programs with the emphasis in the Public Health (Biostatistics, Epidemiology, Prevention), Clinical (Transplantation Biology, Clinical Transplantation, Human Immunogenetics, Immunology, Infectious Disease), Fundamental sciences (Basic, Human Biology), and programs that impact all three disciplines (Breast, Prostate, Gynecologic, Genetics, Imaging, and Genetic Instability). During the next grant period the Consortium will seek to develop additional strength in three areas: (1) To increase scientific collaboration and interactions afforded by the new consortium arrangement. (2) To build on existing strengths in immunologic and molecular approaches to solid tumor diagnosis, treatment and prevention. Prior experience in the development of successful new therapeutic approaches for leukemia and lymphoma and the new partnership in cancer clinical care which has been formed between the members of the Consortium, the Seattle Cancer Care Alliance will also contribute to achieving this goal. (3) The Consortium will be a leader in the application of molecular approaches to population sciences. New laboratories will be dedicated to this objective in the new Public Health Sciences Building currently under construction.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-34S4
Application #
7583619
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1977-01-01
Project End
2008-12-31
Budget Start
2007-01-01
Budget End
2008-12-31
Support Year
34
Fiscal Year
2008
Total Cost
$9,979,932
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications